Our expertise, your success

PCT’s client-focused service model starts with a highly experienced and knowledgeable leadership team that collectively brings together more than 100 years of cell therapy and pharmaceutical development, manufacturing, quality, operations and administration experience. Our leaders have worked on some of the major cell therapies of the past 10 years, and have extensive experience in pharmaceutical-grade quality and operations.
Leadership_Robert_Preti-1.png

Robert A. Preti, PhD

Chief Executive Officer and President

Leadership_Robert_Preti-1.png

Robert A. Preti, PhD

Chief Executive Officer and President

Your vision is our focus. Our passion is your success! Our team is honored each time we earn the opportunity to convert a client to a PCT ambassador.

Robert “Bob” Preti is the co-founder of Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) and the visionary behind its successful growth and development strategy over much of the last two decades. Upon HCATS' acquisition by Hitachi Chemical Co. America, Ltd. (Hitachi Chemical’s consolidated subsidiary) in May 2017, Bob’s role expanded to Chief Executive Officer and President of HCATS, responsible for development, management and oversight of the global business operations of Hitachi Chemical’s regenerative medicine business unit.

Bob built HCATS to meet a recognized need for high quality manufacturing and development services in an emerging industry. As the cell therapy field has grown, so too has HCATS- the company has now served over 100 Clients and performed more than 20,000 cell therapy procedures. His leadership has been instrumental in creating PCT’s Client-focused model that helps bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice. His vision for HCATS includes expansion of its manufacturing capacity in the U.S., Asia and Europe, as well as the development of new technological and engineering innovations that will help streamline and automate many cell processing techniques, leading to faster scale up, appropriate cost of goods, and robust quality for the industry.

Before assuming his role at HCATS, Bob held a number of positions within the cellular therapy and blood banking fields. From 1996 to 1999, he was the director of hematopoietic stem cell processing and applied research at Hackensack University Medical Center in Hackensack, N.J. He served in several capacities with the New York Blood Center from 1990 to 1997, including tissue bank director, director of hematopoietic stem cell processing, scientific director and associate investigator. He also worked as a research scientist for Marrow-Tech Incorporated, which went on to become Advanced Tissue Sciences (ATIS), where work in his laboratory lead to the Dermagraft product currently marketed by Organogenesis.

Bob began his career in academics, teaching first as an elementary and secondary level educator, then as an adjunct assistant professor and lecturer at Hunter College, an assistant professor at Queensborough Community College, and then adjunct assistant professor at York College. He also has served as clinical assistant professor of medicine for New York Medical College in Valhalla, N.Y.

Also active in the public health arena, Bob has served on the Stem Cell Banking Committee and Cord Blood Subcommittee of the New York State Department of Health and on the New Jersey State Department of Health’s Blood Bank Advisory Committee, chairing the Hematopoietic Progenitor Cell Processing Subcommittee. In addition, he has served in a leadership capacity for many professional organizations, including treasurer and founding member of the International Society of Hematotherapy and Graft Engineering, now called ISCT (International Society for Cellular Therapy). He has published and presented extensively on a variety of topics relating to cellular therapies. He recently completed a five year term as a director for AABB, and is currently Chairman for the Alliance for Regenerative Medicine (ARM), where, among other activities, he previously served as Vice Chairman from 2015 to 2016 and co-chaired the Standards and Technology Committee.

Bob holds a BS degree in biology from Fordham University, and a MS degree and Doctorate, both in biology, from New York University

William J. Monteith

William J. Monteith

Chief Operating Officer

William J. Monteith

William J. Monteith

Chief Operating Officer

William Monteith joined Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) in October, 2015. He is a dynamic global pharmaceutical Operations and Quality Executive with a documented record of organizational success and a proven record of accomplishment in strategic planning and execution, business process improvement, cost reduction, FDA and DEA regulatory compliance, facility startup and turnaround, technical transfer and analytical method validation, supply chain, and multi-plant management.

Before joining HCATS, William was VP and General Manager, and then Executive VP, Technical Operations, at immunotherapy biotechnology company Dendreon Corporation. He has also held leadership roles at Sandoz, Shire, and Wyeth pharmaceuticals, ranging from technical operations to quality assurance.

William is a member of the American Chemical Society, the American Society of Quality Professionals, the American Society of Pharmaceutical Scientists, and the International Society of Pharmaceutical Engineers. He received his BS in Chemistry from Saint Lawrence University in Canton, NY.

Mark Westgate, CPA

Mark Westgate, CPA

Chief Financial Officer

Mark Westgate, CPA

Mark Westgate, CPA

Chief Financial Officer

"Our goal is to enable our Clients to improve the lives of patients through cell therapy treatments."

Mark Westgate, CPA joined Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) in 2011 as Vice President, Finance and in 2017 was named Chief Financial Officer. Mark is responsible for the oversight and coordination of all accounting and finance functions at HCATS, playing a key role in managing the company's continued growth. He participates in business development and client relationship activities.

Mark was most recently Chief Financial Officer of Apricus Biosciences, Inc., a publicly traded pharmaceutical research and development company. Prior to this, he was the Controller at Lavipharm Laboratories, Inc., also a pharmaceutical research and development company specializing in drug delivery and particle design.

Mark has over twenty years of public accounting and financial management experience. Mark is a Certified Public Accountant in the State of New York and a member of the New York State Society of Certified Public Accountants. He holds a B.B.A. degree in public accounting from Pace University.

Mark Flower

Mark Flower

Executive Director, Sales and Marketing

Mark Flower

Mark Flower

Executive Director, Sales and Marketing

Mark joined Hitachi Chemical Advanced Therapeutics Solutions (HCATS) in September of 2017, as the Executive Director, Sales and Marketing. In this role he leads marketing, communications, industry intelligence, sales and account management efforts. Mark has over 12 years experience working in the field of oncology, immunotherapy, cellular therapy and bioprocessing.

Prior to joining HCATS Mark worked at Terumo BCT as Senior Manager, Global Strategic Marketing, in the Therapeutic Systems business unit. In this global role he was focused on market research, business development opportunities and established consulting services with developers of cell based gene and immunotherapies. In previous roles Mark successfully launched and maintained commercial responsibility for multiple devices and technologies in the field of stem cell collection via leukapheresis, cell isolation, cell processing and manufacturing. His relationships extend to leading academic and research centers that serve as the clinical trial sites for numerous innovative cell therapies.

Mark is a member of the International Society for Cellular Therapy (ISCT), the Society for Immunotherapy of Cancer (SITC), and graduated from the University of California, San Diego with a BS in Biological Science.

Gayle Gironda

Gayle Gironda

Vice President, Human Resources

Gayle Gironda

Gayle Gironda

Vice President, Human Resources

Gayle joined Hitachi Chemical Advanced Therapeutics Solutions (HCATS) in 2017 as Vice President, Human Resources. In this role, Gayle will lead the company’s efforts to strengthen the PCT brand as an employer-of-choice, attracting and developing the most talented workforce within the cell therapy industry.

Gayle is a seasoned HR executive with significant experience in the Life Sciences. Her work has encompassed global organization design, performance culture, diversity and inclusion strategy, change and transition management, talent acquisition/strategy, compensation and benefits, global commercial operations and rapid expansion in GMP environments.

Gayle has most recently served as Executive Director, HR-Commercial Operations at Alexion Pharmaceuticals from 2012 to 2017. At Alexion, she supported all commercial operations headquartered in North America, with responsibility for the global commercial business build-out, creating a business unit structure and impacting over thirty countries worldwide. Her primary responsibilities included providing counsel and support to eight vice presidents serving global and North American markets.

Prior to Alexion, Gayle served at Allergan (formerly Watson Pharmaceuticals, Inc.) as Executive Director, Global Talent Acquisition from 2009 to 2012. Her twenty year-long career has also included HR positions at Jerini Ophthalmic, OSI-Eyetech, PepsiCo, and Priceline, in addition to HR consulting work.

Gayle received her Bachelor of Arts in Liberal Studies from the State University of New York, College at Purchase, and is near completion of a Masters degree in Organizational Psychology from Columbia University, Teachers College.

George S. Goldberger, MBA

George S. Goldberger, MBA

Vice President, Business Development

George S. Goldberger, MBA

George S. Goldberger, MBA

Vice President, Business Development

"We partner with our clients to reach their goals."

George S. Goldberger;is Vice President, Business Development of Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT). Prior to the acquisition of PCT by NeoStem, he was PCT's Chief Business and Financial Officer. He has held these positions since March 1999.

Before joining PCT, George was President and Chief Executive Officer of Goldberger & Associates Inc., an international management consulting firm with offices in New York, Budapest, and Kiev where they served multinational companies with a focus on health care services. Through Goldberger & Associates, George assisted National Medical Care, now part of Fresenius Medical Care, in establishing and developing dialysis center operations in Europe. Prior to that, George was in charge of mergers and acquisitions at Figgie International, Inc., a diversified conglomerate, today is known as Scott Technologies Inc.

George holds an M.B.A. in finance from the Wharton School of the University of Pennsylvania and a B.S. in systems engineering.

Brian Hampson, ME

Brian Hampson, ME

Vice President, Global Manufacturing Sciences and Technology

Brian Hampson, ME

Brian Hampson, ME

Vice President, Global Manufacturing Sciences and Technology

Brian Hampson is Vice President, Global Manufacturing Sciences and Technology, tasked with leading Hitachi Chemical Advanced Therapeutics Solutions ("HCATS")’s Center for Innovation and Engineering (I&E). I&E was created to help HCATS’ Clients think beyond current practices and to develop long-term solutions to the unique challenges faced by the manufacturers of cell therapy products. PCT’s I&E solutions accelerate the use of automation, integration, closed processing and other strategies to address the important issues of scale up, cost of goods, quality control and robustness of our Client’s manufacturing processes in anticipation of commercial success.

Brian has focused his career primarily on the development of first generation products and related manufacturing processes for the medical and biotechnology markets. He brings an extensive background and broad knowledge of many technical disciplines, including control systems, process automation, software, fluid systems, cell culture processes, aseptic/closed-system processing, and single-use disposable systems.

Prior to joining HCATS, Brian worked for two decades with Aastrom Biosciences in Ann Arbor, Michigan, where he held several positions, most recently as Senior Engineering Fellow, an executive level engineering position tasked with providing strategic technical leadership to cell therapy manufacturing technology. He had previously held the positions at Aastrom of Vice President, Product Development; Senior Director, Product Engineering; and Director, Instrumentation Development. Brian is a thought leader in the application of engineering principles and innovation for the needs of bioreactor systems and the manufacture of cell therapy products, and he was the chief architect for the pioneering patient-specific automation efforts which resulted in the Aastrom Replicell System (ARS).

Brian holds a Master of Engineering, Electrical, and a Bachelor of Science, Electrical Engineering from Cornell University.

Thomas Heathman, PhD

Thomas Heathman, PhD

Business Leader, Technology Development, Manufacturing Development & GTP Services

Thomas Heathman, PhD

Thomas Heathman, PhD

Business Leader, Technology Development, Manufacturing Development & GTP Services

Tom joined Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) in November 2015 as a Business Development Associate and currently acts as the Business Leader in Technology and Product Development. In this role, Tom is responsible for clients’ customer experience as well as the growth, profitability and operational excellence of the technology and product development business line.

Tom’s PhD focused on developing process control strategies for the large-scale manufacture of human mesenchymal stem cells in bioreactors. During his PhD program, Tom was actively involved in business development activities which included leading multiple contract research projects with industry partners, facilitating collaborative projects in regenerative medicine between the UK and Japan, and enabling collaborative presentations and publications. Tom has a Master’s degree in Chemical Engineering from the University of Bath, UK and previously worked as an intern Process Engineer at the BP Research and Technology Centre in the UK where he was responsible for driving the implementation of two key pilot plant projects, leading teams of process specialists to successfully deliver these projects, on time and on budget.

Tom has received a number of prestigious awards in the field, authored multiple original research publications and book chapters on the subject of cell therapy manufacture, and holds a number of committee positions in regenerative medicine.

Sanjin Zvonic, PhD

Sanjin Zvonic, PhD

Senior Director, Business Leader, Clinical and Commercial Manufacturing

Sanjin Zvonic, PhD

Sanjin Zvonic, PhD

Senior Director, Business Leader, Clinical and Commercial Manufacturing

Sanjin joined Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) in April 2016 as Senior Director, Business Leader, Clinical and Commercial Manufacturing. In this role, Sanjin will be responsible for clients’ customer experience as well as the growth, profitability and operational excellence of the manufacturing business line.

Prior to joining HCATS, Sanjin worked at Novartis as Senior Fellow, Technical Research & Development, Cell & Gene Therapy Unit, where he was responsible for the process and product development of a late-stage pipeline product. Before his experience at Novartis, Sanjin initially worked at HCATS from 2009 to 2014 as Director, Technology & Business Development, then from January to July, 2014 as Director, Technology Applications. In this role, Sanjin was responsible for driving the creation of client-specific service platforms designed to address each client’s unique needs and enable their long-term success. He also worked with project managers on technology transfer and performed regulatory and consulting services for clients.

Sanjin’s previous roles include Industrial Liaison/Process Development Director, Tulane University Center for Gene Therapy and Senior Postdoctoral Fellow/ QC Associate, Tulane University Center for Gene Therapy.

Sanjin is the author of more than 20 peer-reviewed articles published in top-tier academic journals, serves as an ad-hoc reviewer on four cell biology journals, and has given more than 30 talks and presentations at both academic and industry events.